Toll Free: 1-888-928-9744

Visceral Pain - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 64 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Visceral Pain - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Visceral Pain - Pipeline Review, H1 2016', provides an overview of the Visceral Pain pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Visceral Pain
- The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects
- The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Visceral Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Visceral Pain Overview 8 Therapeutics Development 9 Pipeline Products for Visceral Pain - Overview 9 Pipeline Products for Visceral Pain - Comparative Analysis 10 Visceral Pain - Therapeutics under Development by Companies 11 Visceral Pain - Therapeutics under Investigation by Universities/Institutes 12 Visceral Pain - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Visceral Pain - Products under Development by Companies 15 Visceral Pain - Products under Investigation by Universities/Institutes 16 Visceral Pain - Companies Involved in Therapeutics Development 17 Addex Therapeutics Ltd 17 Amorepacific Corporation 18 Aros Pharma ApS 19 Astellas Pharma Inc. 20 Echo Pharmaceuticals B.V. 21 GIcare Pharma Inc 22 Grunenthal GmbH 23 Nektar Therapeutics 24 Neurim Pharmaceuticals Ltd 25 Visceral Pain - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 ADX-71441 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ADX-71743 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ASP-7663 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 dronabinol - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 GIC-1002 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NEO-5024 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 NEO-5937 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 NeuP-12 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 NKTR-195 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 PAC-14028 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 piromelatine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PPC-5650 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 PR-38 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 RO-656570 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 URB-937 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Visceral Pain - Recent Pipeline Updates 56 Visceral Pain - Dormant Projects 60 Visceral Pain - Discontinued Products 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Visceral Pain, H1 2016 9 Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Visceral Pain - Pipeline by Addex Therapeutics Ltd, H1 2016 17 Visceral Pain - Pipeline by Amorepacific Corporation, H1 2016 18 Visceral Pain - Pipeline by Aros Pharma ApS, H1 2016 19 Visceral Pain - Pipeline by Astellas Pharma Inc., H1 2016 20 Visceral Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2016 21 Visceral Pain - Pipeline by GIcare Pharma Inc, H1 2016 22 Visceral Pain - Pipeline by Grunenthal GmbH, H1 2016 23 Visceral Pain - Pipeline by Nektar Therapeutics, H1 2016 24 Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Visceral Pain Therapeutics - Recent Pipeline Updates, H1 2016 56 Visceral Pain - Dormant Projects, H1 2016 60 Visceral Pain - Dormant Projects (Contd..1), H1 2016 61 Visceral Pain - Discontinued Products, H1 2016 62


List of Figures
Number of Products under Development for Visceral Pain, H1 2016 9 Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Top 10 Targets, H1 2016 27 Number of Products by Stage and Top 10 Targets, H1 2016 27 Number of Products by Top 10 Mechanism of Actions, H1 2016 29 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Molecule Types, H1 2016 33 Number of Products by Stage and Molecule Types, H1 2016 33

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify